2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2939 Plasma-induced gene expression modules are associated with pain frequency in children with sickle cell disease and facilitate the understanding of pain biology

Mehri Bagherimohamadipour, PhD, Shuang Jia2, Ashima Singh, PhD, MS3, Mark Roethle4, Joshua Field, MD5, Dawn Retherford, BS6, Janelle Highland, BS, MS7, Jessica J Rico, BS8, Nicole Steiner, BS9, Martin Hessner10, Amanda M Brandow, DO, MS11
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Despite sharing the same hemoglobin mutation, individuals with sickle cell disease (SCD) exhibit substantial variability in acute pain frequency, suggesting factors beyond the hemoglobin mutation contribute to pain heterogeneity. Plasma-based circulating mediators may provide insight into pain heterogeneity; however, measuring individual mediators does not capture complex in vivo interactions. Integrating plasma-induced gene transcription with clinical pain data may provide a more comprehensive assessment of the plasma milieu influencing pain variability. We sought to identify plasma-induced gene expression signatures associated with acute pain frequency in children with SCD. We hypothesized signatures would reveal coordinated transcriptional networks and biological pathways associated with pain frequency and identify candidate mechanisms underlying interindividual pain variability.

Children (<19 yrs) with SCD and healthy Black controls were enrolled; all were in baseline health (no acute care within ≥2 weeks) when plasma was collected. Medical record data collected included acute care visits for SCD pain (emergency department treatment and discharge, hospitalizations) for 5 years prior to plasma collection. Individuals were classified as high pain frequency if they had >0.75 SCD pain visits per year during the 5-year period; those with <0.4 pain visits per year had low pain frequency.  Plasma from SCD individuals and controls were incubated with peripheral blood mononuclear cells (PBMCs) drawn from a healthy donor. Genome-wide transcriptional PBMC responses were measured using the Affymetrix HG-U133 Plus 2.0 microarray. Gene expression data were filtered using third-quartile expressions and median absolute deviation metrics to retain highly expressed and variable transcripts. Differential expression analysis between SCD and controls identified genes with a fold change >1.4, ANOVA p<0.05, FDR<10%. Weighted Gene Co-expression Network Analysis (WGCNA) identified co-expressed gene modules associated with pain frequency. Modules with a correlation coefficient of |r|≥0.30, p<0.05 were retained. Heatmaps created with Genesis visualized gene expression patterns and clustering. Gene Ontology biological process enrichment was performed for WGCNA modules significantly associated with pain frequency. Pain-associated probe sets were visualized using Genesis hierarchical clustering with genes ordered to module membership (kME) to identify highly connected hub genes and coordinated expression patterns.

We enrolled 54 children with SCD (mean (SD) age 8.9 (4.7) yrs; 48% female; majority HbSS) and 21 controls (mean (SD) age 11.7 (3.8) yrs; 38% female). After gene filtering and differential expression analysis, 4881 genes were identified and used as input for WGCNA. WGCNA identified 11 distinct modules, of which 6 were significantly associated with pain frequency. The 6 modules were comprised of 319, 410, 46, 95, 96, 884 genes. Heatmaps show differential gene expression patterns between SCD individuals with high and low pain frequency. Importantly, patterns support distinct endotypes that separate based on pain frequency and clustering of gene expression. Hierarchical clustering of the 1,227 pain-associated genes (|r|≥0.30, p<0.05) identified coordinated expression patterns and highly connected hub genes within pain-associated modules, supporting distinct plasma-induced transcriptional signatures as sociated with pain frequency. Functional enrichment analysis of modules significantly associated with pain frequency reveal pathways related to immune and inflammatory signaling (e.g., interferon and IL-18 pathways, T-cell cytotoxicity), neuronal and synaptic function (e.g., GABAergic signaling, neurotransmitter receptor regulation, axonal transport), ciliary motility, metabolic and epigenetic regulation (e.g., citrulline and glycolipid metabolism, DNA replication, epigenetic gene regulation), muscle function and regeneration, and RNA processing (all p<0.01). These findings suggest pain frequency is associated with coordinated alterations in neuroimmune signaling, sensory processing, tissue remodeling, cellular metabolism, and post-transcriptional regulation.

Plasma-induced gene expression profiling identified transcriptional networks associated with acute pain frequency in children with SCD, revealing potential molecular pathways underlying pain. Future studies will further characterize these pathways and their biological consequences.

Amanda M Brandow, DO, MS: Pfizer - Consultancy (Includes expert testimony)